Small interfering ribonucleic acid design strategies for effective targeting and gene silencing

Expert Opinion on Drug Discovery

Volumn 6, Issue 3, 2011, Pages 269-289

  Malhotra, Meenakshi ^a   Nambiar, Shruti ^b   Rengaswamy, Venkatesh ^c   Prakash, Satya ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF WATERLOO   (Canada)

^c INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

Author keywords

efficient delivery; gene silencing; off target effect; RNA interference; siRNA chemical modifications siRNA delivery; siRNA design algorithms; siRNA design rules

Indexed keywords

2' FLUOROCYTIDINE; 2' FLUOROPYRIMIDINE; 2' FLUOROURIDINE; 2' O METHYLENE; CARBENE; CELL PENETRATING PEPTIDE; CYSTEINE; CYTIDINE DERIVATIVE; DICER; DOUBLE STRANDED RNA; FLUORINE; GLYCINE; LIPOSOME; LNA OLIGONUCLEOTIDE; MESSENGER RNA; OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID; PYRIMIDINE DERIVATIVE; RIBOSE; RNA DERIVATIVE; RNA INDUCED SILENCING COMPLEX; SINGLE STRANDED RNA; SMALL INTERFERING RNA; SMALL INTERNALLY SEGMENTED INTERFERING RNA; STICKY SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNLOCKED NUCLEIC ACID; URIDINE DERIVATIVE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; AMINO ACID SEQUENCE; CHEMICAL MODIFICATION; COMBINATORIAL LIBRARY; COMPUTATIONAL FLUID DYNAMICS; CYTOLOGY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG STABILITY; DRUG SYNTHESIS; GENE; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENETIC ALGORITHM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA DEGRADATION; RNA INTERFERENCE; STRUCTURE ACTIVITY RELATION; THERMODYNAMICS;

EID: 79952238110     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2011.555394     Document Type: Review

References (129)

1. Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible cosuppression of homologous genes in trans. Plant Cell 1990;2:279-89 (Pubitemid 120029588)
2. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-11 An important discovery of the function of RNA interference mechanism that depends on hybridization between the injected RNA and endogenous messenger RNA transcripts.
3. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in mammalian cell culture. Nature 2001;411:494-8 The first demonstration of gene silencing in mammalian cell lines including human embryonic kidney and HeLa cells by 21-nucleotide siRNAs.
4. Hammond SM, Boettcher S, Caudy AA, et al. Argonaute2, a link between genetic and biochemical analyses of RNAi. Science 2001;293:1146-50 (Pubitemid 32758097)
5. Sharp PA. RNA interference-2001. Genes Dev 2001;15:485-90
6. Hutvagner G, Zamore PD. RNAi: nature abhors a double-strand. Curr Opin Genet Dev 2002;12:225-32 (Pubitemid 34219496)
7. Kim DH, Behlke MA, Rose SD, et al. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 2005;23:222-6 Described that siRNAs with 25 - 30 base length range can have as much as a 100-fold increase in potency compared with 21-mer at the same location.
8. Elbashir SM, Martinez J, Patkaniowska A, et al. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 2001;20:6877-88 (Pubitemid 33134217)
9. Reynolds A, Leake D, Boese Q, et al. Rational siRNA design for RNA interference. Nat Biotechnol 2004;22:326-30 Proposed eight characteristics associated with siRNA functionality that significantly improves potent siRNA selection.
10. Ui-Tei K, Naito Y, Takahashi F, et al. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res 2004;32:936-48 Demonstrated the relationship between siRNAs and RNA interference and proposed four rules based on siRNAs inducing effective gene silencing in mammalian and chick cells.
11. Amarzguioui M, Prydz H. An algorithm for selection of functional siRNA sequences. Biochem Biophys Res Commun 2004;316:1050-8 Compared the features that consistently correlated positively with functionality across the data sets of 19bp duplex siRNAs and proposed the rule sets.
12. Pei Y, Tuschl T. On the art of identifying effective and specific siRNAs. Nat Methods 2006;3:670-6 An excellent review summarizing most of the selection criteria and emphirical guidelines.
13. Holen T, Amarzguioui M, Wiiger MT, et al. Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor. Nucleic Acids Res 2002;30:1757-66 (Pubitemid 34679753)
14. Echeverri CJ, Beachy PA, Baum B, et al. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods 2006;3:777-9 (Pubitemid 44445821)
15. Schwarz D, Hutvagner G, Du T, et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003;115:199-208 (Pubitemid 37329583)
16. Jackson AL, Bartz SR, Schelter J, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003;21:635-7 Demonstrated the off-target silencing problem on a genome-wide scale and confirmed that siRNAs may crossreact with targets of limited sequence similarity.
17. Khvorova A, Reynolds A, Jayasena JD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003;115:209-16 Demonstrated the thermodynamic properties of siRNA that play a critical role in determining the activity by biasing the steps involved in duplex unwinding and strand retention by RISC.
18. Tomari Y, Matranga C, Haley B, et al. A protein sensor for siRNA asymmetry. Science 2004;306:1377-80 (Pubitemid 39532515)
19. Haley B, Zamore PD. Kinetic analysis of the RNAi enzyme complex. Nat Struct Mol Biol 2004;11:599-606 (Pubitemid 38823525)
20. Hohjoh H. Enhancement of RNAi activity by improved siRNA duplexes. FEBS Lett 2004;557:193-8 (Pubitemid 38115894)
21. Holen T, Moe SE, Sorbo JG, et al. Tolerated wobble mutations in siRNAs decrease specificity, but can enhance activity in vivo. Nucleic Acids Res 2005;33:4704-10 (Pubitemid 41418872)
22. Overhoff M, Alken M, Kretschmer-Kazemi R. Local RNA target structure influences siRNA efficacy: a systemic global analysis. J Mol Biol 2005;348:871-81 (Pubitemid 40544388)
23. Yoshinari K, Miyagishi M, Taira K. Effects on RNAi of the tight structure, sequence and position of the targeted region. Nucleic Acids Res 2004;32:691-9 (Pubitemid 38263060)
24. Yuan B, Latke R, Mossback M, et al. siRNA Selection Server: an automated siRNA oligonucleotide prediction server. Nucleic Acids Res 2004;32:W130-4
25. Persengiev SP, Zhu X, Green MR. Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 2004;10:12-18 (Pubitemid 38018731)
26. Birmingham A, Anderson EM, Reynolds A, et al. 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 2006;3:199-204 An extensive analysis of off-targeted genes identified by expression profiling that proved off-targeting is associated with 3′ UTR seed-region matches of the antisense strand of the siRNA.
27. Anderson EM, Birmingham A, Baskerville S, et al. Experimental validation of the importance of seed complement frequency to siRNA specificity. RNA 2008;4:853-61 The first experimentally validated strategy for designing siRNAs with effective off-target reduction and enhanced specificity based on 3′ UTR seed complement frequencies.
28. Stein P, Zeng F, Pan H, et al. Absence of non-specific effects of RNA interference triggered by long double-stranded RNA in mouse oocytes. Dev Biol 2005;286:464-71 (Pubitemid 41443285)
29. Cullen BR. Enhancing and confirming the specificity of RNAi experiments. Nat Methods 2006;3(9):677-81 (Pubitemid 44275733)
30. Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005;11:263-70 (Pubitemid 40460553)
31. Judge AD, Sood V, Shaw JR, et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005;23:457-62 Identified putative immunostimulatory motifs that have allowed the design of siRNAs that can mediate RNAi but induce minimal immune activation.
32. Poeck H, Besch R, Maihoefer C, et al. 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med 2008;14:1256-63
33. Schlee M, Hornung V, Hartmann G. siRNA and isRNA: two edges of one sword. Mol Ther 2006;14:463-70 (Pubitemid 44296098)
34. Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides 2008;18:305-19 (Pubitemid 352791344)
35. Eberle F, Giessler K, Deck C, et al. Modifications in small interfering RNA that separate immunostimulation from RNA interference. J Immunol 2008;180:3229-37
36. Gantier MP, Tong S, Behlke MA, et al. Rational design of immunostimulatory siRNAs. Mol Ther 2010;18:785-95
37. Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010;9:57-67
38. Bramsen JB, Laursen MB, Nielsen AF, et al. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res 2009;37:2867-288 Compared the effect of 21 types of chemical modifications on siRNA activity and toxicity in a total of 2160 siRNA duplexes.
39. Chiu YL, Rana TM. SiRNA function in RNAi: a chemical modification analysis. RNA 2003;9:1034-48 Tested various chemical modifications in siRNAs to determine the biochemical properties required for RNA interference.
40. Rana TM. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 2007;8:23-36 An excellent review on RNAi machinery.
41. Chiu YL, Rana TM. RNAi in human cells: basic structural and functional features of small interfering RNA. Mol Cell 2002;10:549-61 (Pubitemid 35284173)
42. Czauderna F, Fechtner M, Dames S, et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003;31:2705-16 (Pubitemid 37442115)
43. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432:173-8 (Pubitemid 39545841)
44. Muhonen P, Tennila T, Azhayeva E, et al. RNA interference tolerates 2′-fluoro modifications at the Argonaute2 cleavage site. Chem Biodivers 2007;4:858-73 (Pubitemid 46930002)
45. Layzer JM, McCaffrey AP, Tanner AK, et al. In vivo activity of nuclease-resistant siRNAs. RNA 2004;10:766-71
46. Jackson AL, Burchard J, Leake D, et al. Position specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 2006;12:1197-205 Demonstrated that 2′-O-methyl ribosyl substitution at position 2 in the guide strand reduced silencing of most off-target transcripts with complementarity to the seed-region of the siRNA guide strand.
47. Robbins M, Judge A, Liang L, et al. 2′-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther 2007;15:1663-9 Demonstrated that 2′OMe-modified RNA acts as a potent inhibitor of RNA-mediated cytokine induction by deterring TLR7.
48. Bolcato-Bellemin AL, Bonnet ME, Creusat G, et al. Sticky overhangs enhance siRNA-mediated gene silencing. PNAS 2007;104:16050-5 (Pubitemid 350099361)
49. Bramsen JB, Laursen MB, Damgaard CK, et al. Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res 2007;35:5886-97 Described a novel three-stranded siRNA construct composed of an intact antisense strand complemented with two shorter 10-12 nucleotide sense strands that are highly functional and completely eliminating offtargeting.
50. Leuschner PJ, Ameres SL, Kueng S, et al. Cleavage of the siRNA passenger strand during RISC assembly in human cells. EMBO Rep 2006;7:314-20
51. Elmen J, Thonberg H, Ljungberg K, et al. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 2005;33:439-47 (Pubitemid 40276964)
52. Mook OR, Baas F, de Wissel MB, et al. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol Cancer Ther 2007;6:833-43 (Pubitemid 46554553)
53. Werk D, Wengel J, Wengel SL, et al. Application of small interfering RNAs modified by unlocked nucleic acid (UNA) to inhibit the heart-pathogenic coxsackievirus B3. FEBS Lett 2010;584:591-8
54. Kenski DM, Cooper AJ, Li JJ, et al. Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5′-terminal phosphorylation both in vitro and in vivo. Nucleic Acids Res 2010;38:660-71
55. Bramsen JB, Pakula MM, Hansen TB, et al. A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res 2010;38:5761-73
56. Vaish N, Chen F, Seth S, et al. Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs. Nucleic Acids Res 2010:1-10
57. Sullivan YB, Hughes DE, Narahari J, et al. Importance of siRNA negative control selection: evaluation of non-specific protein knock-down by negative control siRNA. J Immunol 2007;178:87.42
58. Zhou H, Zeng X, Wang Y, et al. A three-phase algorithm for computer aided siRNA design. Informatica 2006;30:357-64 (Pubitemid 44860837)
59. Schubert S, Grunweller A, Erdmann VA, et al. Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions. J Mol Biol 2005;348:883-93 (Pubitemid 40544389)
60. Heale BS, Soifer HS, Bowers C, et al. siRNA target site secondary structure predictions using local stable substructures. Nucleic Acids Res 2005;33:e30 Proposed a novel secondary structure prediction method and duplex-end differential calculations to analyze the importance of a secondary structure in the siRNA design to eliminate the non-functional sites.
61. Yiu SM, Prudence WH, Lam TW, et al. Filtering of ineffective siRNAs and improved siRNA design tool. Bioinformatics 2005;21:144-51 Formulated effective filtering algorithm based on the observations of the secondary structure that is verified by AI techniques such as decision trees and support vector machines.
62. Matveeva O, Nechipurenko Y, Rossi L, et al. Comparison of approaches for rational siRNA design leading to a new efficient and transparent method. Nucleic Acids Res 2007;35:e63 Compared different approaches of siRNA design and developed a new method based on linear regression fitting with local duplex stability, nucleotide position-dependent preferences and total G/C content of siRNA duplexes.
63. Takasaki S. Efficient prediction methods for selecting effective siRNA sequences. Comput Biol Med 2010;40:149-58 Combined method of the Radial Basis Function network and decision tree learning for selecting effective siRNA target sequences.
64. Klingelhoefer JW, Moutsianas L, Holmes C. Approximate Bayesian feature selection on a large meta-dataset offers novel insights on factors that effect siRNA potency. Bioinformatics 2009;25:1594-601
65. Hu W, Hu J. Prediction of siRNA potency using sparse logistic regression. J Comput Biol 2010;18:1-8
66. Walton SP, Wu M, Gredell JA, Chan C. Designing highly active siRNAs for therapeutic applications. FEBS J 2010;277:4806-13
67. Tiemann K, Hohn B, Ehsani A, et al. Dual-targeting siRNAs. RNA 2010;6:1275-84
68. Chang CI, Kang HS, Ban C, et al. Dual-target gene silencing by using long, synthetic siRNA duplexes without triggering antiviral responses. Mol Cells 2009;30:689-95
69. Grimn D, Kay MA. Combinatorial RNAi: a winning strategy for the race against evolving targets. Mol Ther 2007;15:878-88 (Pubitemid 46621646)
70. Ehsani A, Saetrom P, Zhang J, et al. Rational design of micro-RNA-like bifunctional siRNAs targeting HIV and the HIV coreceptor CCR5. Mol Ther 2010;18:796-802
71. Lu PY, Xie F, Woodle MC. In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet 2005;54:117-42
72. Morar AS, Schrimsher JL, Mark D. Pegylation of proteins a structural approach. Biopharm Int 2006;19:34-49
73. Schiffelers RM, Mixsonb AJ, Ansari AM, et al. Transporting silence: design of carriers for siRNA to angiogenic endothelium. J Control Release 2005;109:5-14 (Pubitemid 41737248)
74. McNeil SE. Nanotechnology for the biologist. J Leukoc Biol 2005;78:585-94 (Pubitemid 41292080)
75. Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vision 2003;9:210-16 (Pubitemid 38097589)
76. Tolentino MJ, Brucker AJ, Fosnot J, et al. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 2004;24:132-8 (Pubitemid 38240851)
77. Shen J, Samul R, Silva RL, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006;13:225-34 (Pubitemid 43148645)
78. Nakamura H, Siddiqui SS, Shen X, et al. RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis. Mol Vision 2004;10:703-11 (Pubitemid 41358224)
79. Bitko V, Musiyenko A, Shulyayeva O, et al. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005;11:50-5 (Pubitemid 40215837)
80. Li BJ, Tang Q, Cheng D, et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med 2005;11:944-51 (Pubitemid 41294439)
81. Thakker DR, Natt F, Husken D, et al. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci USA 2004;101:17270-5 (Pubitemid 39627809)
82. Thakker DR, Natt F, Husken D, et al. siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain. Mol Psychiatry 2005;10:782-9 (Pubitemid 41129051)
83. Dorn G, Patel S, Wotherspoon G, et al. SiRNA relieves chronic neuropathic pain. Nucleic Acids Res 2004;32:e49
84. Luo MC, Zhang DQ, Ma SW, et al. An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Mol Pain 2005;1:29
85. Tan PH, Yang LC, Shih HC, et al. Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther 2005;12:59-66
86. Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 2009;61:850-62
87. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009;8:129-38
88. de Fougerolles A, Vornlocher HP, Maraganore J, et al. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007;6:443-53 (Pubitemid 47064567)
89. Chen SH, Zhaori G. Potential clinical applications of siRNA technique: benefits and limitations. Eur J Clin Invest 2010: DOI: 10.1111/j.1365-2362. 2010.02400.x
90. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145-60 (Pubitemid 40282557)
91. MacLachlan I. In: Crooke ST, editor, Antisense drug technology: principles, strategies and applications. 2nd edition. Chapter 9. CRC, Boca Raton; 2007. p. 237-70
92. Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987;84:7413-17
93. Malone RW, Felgner PL, Verma IM. Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci USA 1989;86:6077-81 (Pubitemid 19210605)
94. Zimmermann TS, Lee ACH, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441:111-14
95. Geisbert TW, Hensley LE, Kagan E, et al. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis 2006;193:1650-7 (Pubitemid 43839469)
96. Santhakumaran LM, Thomas T, Thomas TJ. Enhanced cellular uptake of a triplex-forming oligonucleotide by nanoparticle formation in the presence of polypropylenimine dendrimers. Nucleic Acids Res 2004;32:2102-12 (Pubitemid 38854766)
97. Hollins AJ, Benboubetra M, Omidi Y, et al. Evaluation of generation 2 and 3 poly(propylenimine) dendrimers for the potential cellular delivery of antisense oligonucleotides targeting the epidermal growth factor receptor. Pharm Res 2004;21:458-66 (Pubitemid 38338982)
98. Choi YS, Thomas T, Kotlyar A, et al. Synthesis and functional evalution of DNA-assembled polyamidoamine dendrimer clusters for cancer cell-specific targeting. Chem Biol 2005;12:35-43 (Pubitemid 40118324)
99. Urban-Klein B, Werth S, Abuharbeid S, et al. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005;12:461-6 (Pubitemid 40394299)
100. Grzelinski M, Urban-Klein B, Martens T, et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 2006;17:751-66 (Pubitemid 44100720)
101. Hu-Lieskovan S, Heidel JD, Bartlett DW, et al. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005;65:8984-92 (Pubitemid 41377390)
102. Heidel JD, Yu Z, Liu JYC, et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA 2007;104:5715-21 (Pubitemid 47175600)
103. Bartlett DW, Davis ME. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA containing nanoparticles. Biotechnol Bioeng 2008;99:975-85 (Pubitemid 351316639)
104. Howard KA, Rahbek UL, Liu X, et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 2006;14:476-84 (Pubitemid 44296092)
105. Pille JY, Li H, Blot E. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum Gene Ther 2006;17:1019-26 (Pubitemid 46076743)
106. Ochiya T, Takahama Y, Nagahara S, et al. New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet. Nat Med 1999;5:707-10 (Pubitemid 29289437)
107. Hanai K, Takeshita F, Honma K, et al. Atelocollagen-mediated systemic DDS for nucleic acid medicines. Ann NY Acad Sci 2006;1082:9-17 (Pubitemid 44955443)
108. Takeshita F, Minakuchi Y, Nagahara S, et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 2005;102:12177-82 (Pubitemid 41291148)
109. Cheng K, Ye Z, Guntaka RV, et al. Enhanced hepatic uptake and bioactivity of type alpha1 (I) collagen gene promoter-specific triplex-forming oligonucleotides after conjugation with cholesterol. J Pharmacol Exp Ther 2006;317:797-805
110. McNamara JO, Andrechek ER, Wang Y, et al. Cell type-specific delivery ofsiRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006;24:1005-15 (Pubitemid 44215395)
111. Chu TC, Twu KY, Ellington AD, et al. Aptamer mediated siRNA delivery. Nucleic Acids Res 2006;34:e73
112. Muratovska A, Eccles MR. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett 2004;558:63-8 (Pubitemid 38167411)
113. Simeoni F, Morris MC, Heitz F, et al. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res 2003;31:2717-24 (Pubitemid 37442116)
114. Kim WJ, Christensen LV, Jo S, et al. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol Ther 2006;14:343-50 (Pubitemid 44184964)
115. Schiffelers RM, Ansari A, Xu J, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004;32:e149
116. Eguchi A, Meade BR, Chang Y-C, et al. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nature biotechnology 2009;7:567-71
117. Martinez J, Patkaniowska A, Urlaub H. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002;110:563-74 (Pubitemid 35247837)
118. Saetrom P, Snove O. A comparison of siRNA efficacy predictors. Biochem Biophys Res Commun 2004;321:247-53 Compared the performance of different design algorithms and concluded that the siRNAs' sequence is sufficient input to siRNA efficacy algorithms.
119. Boese Q, Leake D, Reynolds A, et al. Mechanistic insights aid computational short interfering RNA design. Methods Enzymol 2005;392:73-96 (Pubitemid 40092509)
120. Jayasena SD. Designer siRNAs to overcome the challenges from the RNAi pathway. J RNAi Gene Silencing 2006;2:109-17 A short review summarizing different ideas to over come the challenges in design and delivery.
121. Tanaka T, Mangala LS, Vivas-Mejia PE, et al. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res 2010;70:3687-96
122. Park YK, Park SM, Choi YC, et al. AsiDesigner: exon-based siRNA design server considering alternative splicing. Nucleic Acids Res 2008;36:W97-103
123. Vert JP, Foveau N, Lajaunie C, et al. An accurate and interpretable model for siRNA efficacy prediction. BMC Bioinformatics 2006;30:7:520
124. Horn T, Boutros M. E-RNAi: a web application for the multi-species design of RNAi reagents - 2010 update. Nucleic Acids Res 2010;38:W332-9
125. Lu ZJ, Mathews DH. The efficient siRNA selection using hybridization thermodynamics. Nuclear Acids Res 2008;36:640-7 (Pubitemid 351250454)
126. Naito Y, Yoshimura J, Morishita S, Ui-Tei K. siDirect 2.0: updated software for designing functional siRNA with reduced seed-dependent off-target effect. BMC Bioinformatics 2009;10:392
127. Gong W, Ren Y, Zhou H, et al. siDRM: an effective and generally applicable online siRNA design tool. Bioinformatics 2008;24:2405-6
128. Chalk AM, Sonnhammer EL. siRNA specificity searching incorporating mismatch tolerance data. Bioinformatics 2008;24:1316-17 (Pubitemid 351659633)
129. Wang X, Wang X, Rajeev K, et al. Selection of hyper-functional siRNAs with improved potency and specificity. Nucleic Acids Res 2009;37:e152